Antares Pharma to add more subjects to QST study in Q3; regulatory submission likely to be mid-to-late 2016

• Based on guidance from the FDA, Antares Pharma (ATRS +2.4%) will add 70 more patients to its Phase 3 clinical trial assessing its QuickShot (QST) auto injector in testosterone-deficient adult males. The patients will be required to be exposed to QST for six months so the company's regulatory filing will be mid-to-late 2016 based on a Q3 2015 start.
• Previously: Antares Pharma's QuickShot auto injector successful in Phase 3 testosterone trial (Feb. 25)